

Special Issue

Association Studies in Clinical Pharmacogenetics—Volume II

Message from the Guest Editors

The progress of Clinical Pharmacogenetics has been remarkable. Its implementation in the United States and Europe is gradually increasing. At the regulatory level, agencies such as the American Food and Drug Administration (FDA) or the European Medicines Agency (EMA) already incorporate genotyping indications in drug labels. In addition, other consortia such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) or the Dutch Pharmacogenetics Working Group (DPWG) or national societies such as the Spanish Society of Pharmacogenetics and Pharmacogenomics (SEFF) develop pharmacogenetic clinical guidelines with prescribing recommendations based on patient's genotype. The drafting of such guidelines depends on the generation of pharmacogenetic evidence, which is collected and, eventually, associations with a high level of evidence are established that may require a dose adjustment or drug change. The aim is to compile sound works from any field of pharmacology that will increase the pharmacogenetic knowledge of drugs without previous clinical validation. Papers that generate new and previously unpublished evidence will also be considered.

Guest Editors

Prof. Dr. Francisco Abad Santos

Princesa Multidisciplinary Initiative for the Implementation of Pharmacogenetics (PriME-PGx), Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, 28006 Madrid, Spain

Dr. Pablo Zubiaur

Princesa Multidisciplinary Initiative for the Implementation of Pharmacogenetics (PriME-PGx), Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, 28006 Madrid, Spain

Deadline for manuscript submissions

closed (24 April 2024)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 7.9
Indexed in PubMed



mdpi.com/si/149817

Pharmaceutics
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 7.9
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).